Department of Vermont Health Access
Pharmacy Benefits Management Program

DUR Board Meeting Agenda

December 11, 2012   6:00 – 8:30 p.m.

PLEASE NOTE NEW START TIMES – PUBLIC SESSION STARTS AT 6:30 PM

1. Executive Session 6:00 - 6:30
   - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements
     (as provided by 33 VSA § 1998(f)(2))

2. Introductions and Approval of DUR Board Minutes 6:30 - 6:35
   (Public Comment Prior to Board Action)

3. DVHA Pharmacy Administration Updates 6:35 - 6:45
   - Updates

4. Medical Director Update 6:45 - 6:45
   - Clinical Programs Update
   - Prescriber Comments

5. Follow-up Items from Previous Meetings 6:45 - 7:00
   - Atypical Antipsychotic Medications – Pediatric Use

6. RetroDUR/DUR 7:00 – 7:30
   - Hepatitis C Protease Inhibitors
   - Narcotic Analgesics – continued use of short acting with no long acting
   - New Topics – Board Discussion of Possible Topics

7. Clinical Update: Drug Reviews 7:30 – 8:00
   (Public comment prior to Board action)

Abbreviated New Drug Reviews
   - Combivent® (ipratropium bromide/albuterol) Respimat
   - QNASL® (beclomethasone dipropionate HFA) Nasal Spray
   - Subsys® (fentanyl) Sublingual Spray

Full New Drug Reviews
   - Arcapta® (indacaterol) Neoalher
   - Dymista® (azelastine/fluticasone) Nasal Spray
   - Korlym® (mifepristone) Oral Tablet
   - Zetonna® (iclesonide) Nasal Aerosol
8. Therapeutic Drug Classes – Periodic Review  8:00 – 8:10
   (Public comment prior to Board action)
   Class review documents available on DVHA web site 12/11/2012 @ 12 Noon
   - Restless Leg Syndrome Medications (including Neupro®)

9. New Managed Therapeutic Drug Classes  8:10 – 8:10
   (Public comment prior to Board action)
   - None

10. Review of Newly-Developed/Revised  8:10 – 8:20
    Clinical Coverage Criteria and/or Preferred Products
    (Public comment prior to Board action)
    - Diabetic Testing Supplies
    - Pancreatic Enzymes

11. General Announcements  8:20– 8:30
    Selected FDA Safety Alerts
    - Fungal Meningitis Outbreak Originating from Compounding Pharmacy
    - Pradaxa®: Update on Safety Review
    - Pramipexole: Possible Risk of Heart Failure

12. Adjourn  8:30